サインイン 無料でサインアップします。

Cotinga Pharmaceuticalsの将来のP / E

Cotinga Pharmaceuticalsの将来のP / Eは何ですか。

Cotinga Pharmaceuticals, Inc.の将来のP / Eは-1.63です。

将来のP / Eの定義は何ですか。



未来比率P / E (株価収益率)は、企業の株価と今後12ヶ月間の1株当たり利益見込額との比率です。

The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.

TSXVのセクタHealth Careにおける将来のP / Eの企業と比べるCotinga Pharmaceuticals

Cotinga Pharmaceuticalsは何をしますか。

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

Cotinga Pharmaceuticalsと類似の将来のp / e